Medicine preparation for treating infantile migraine

Abstract

The invention relates to a medicine preparation for treating infantile migraine. The medicine preparation is prepared from the following medicinal raw materials in parts by weight: 10-30 parts of pilea mongolica, 20-30 parts of calceolaria, 10-30 parts of asplenium pekinense hance, 1-20 parts of canscora lucidissima, 1-10 parts of meliosma rigida, 1-20 parts of henry clematis root, 10-30 parts of lespedesa virgata, 10-20 parts of evergreen mucuna root and leaf, 1-20 parts of common adenostema herb, 10-30 parts of elatostema oblohgifolium fu, 10-30 parts of asplenium yunnanense franch, 1-20 parts of acmella ciliate, 10-20 parts of polygomun aviculane, 10-20 parts of tirpitzia ovoidea, 10-20 parts of Chinese enkianthus, 10-30 parts of bredia amoena, 1-10 parts of denseleaf crazyweed herb, 10-30 parts of phtheirospermum japonicum, 10-30 parts of kazinoki broussonetia, 1-20 parts of actinidia arguta, 1-20 parts of cymbidium hookerianum, 1-20 parts of filamental flowering crab and 10-20 parts of licorice root. The medicine preparation for treating infantile migraine is reasonable in formula, and has a remarkable curative effect on symptoms of infantile migraine.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a medicament for treating migraine in children. Background technique [0002] Migraine is a neurovascular headache with periodic attacks, and it is a common and refractory clinical disease. Epidemiological data show that the incidence rate of migraine is 8.4%-28%, and the lifetime prevalence rate reaches 14%. About 23% of families have at least one migraine patient. Migraine is not a disease unique to adults, but it is also a frequently-occurring disease in children, a special population. At present, most scholars believe that migraine in children is a common chronic recurrent neurovascular disease mainly caused by genetic factors and various environmental factors. Studies have shown that 42.6% of children between the ages of 5 and 13 suffer from headaches, of these children, 3.4% are diagnosed with migraine, and 8.7% are diagnosed as possible migraine. The incidence of migraine in chi...

AI Technical Summary

Problems solved by technology

Although the efficacy of some western medicines in the treatment of acute attacks of migraine in children or the prevention of attacks has been recognized by evidence-based medicine, there are often side effects such as dependence after taking the drugs in the acute stage, and the long-term effect is not satisfactory. There are many adverse drug reactions, and children and adolescents are in an important stage of physical development. Due to poor treatment effects and adverse drug reactions, they can cause varying degrees of damage to the physical and mental health of children and adolescents.